Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05046639 · ClinicalTrials.gov registry record · Phase 4

Sciatic Block in Contralateral Limb Phantom and Residual Limb Pain

A Phase 4 study, sponsored by Northwestern University.

Terminated
Registry status
Phase 4
Development phase
1
Enrollment target

NCT05046639 is a Phase 4 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 1 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05046639, a Phase 4 study, was terminated before completion, sponsored by Northwestern University.

TERMINATED
Registry status
Phase 4
Development phase
1 participants
Enrollment target

Study Summary

Participants with chronic, refractory phantom limb pain (PLP) or residual limb pain (RLP) for more than 6 months will be enrolled in this clinical trial. Aim: Define the attributable pain relief and functional improvement in participants with PLP/RLP after contralateral limb sciatic nerve block. Also, contribute to the basic science understanding of the crossed-withdraw reflex by demonstrating a known animal model phenomenon in human participants. Hypothesis: Contralateral limb sciatic nerve anesthetic block with 2% lidocaine provides immediate clinically meaningful pain reduction, defined as the proportion of patients with at least 50% improvement in numeric rating scale (NRS) pain score in PLP/RLP when compared to sham.

Interventions

  • DRUG 10 mL 2% lidocaine
  • DRUG 10 mL preservative free saline

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2021-09-01
Est. Completion 2023-07-26
Phase Phase 4

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT05046639

The ClinicalTrials.gov registry entry for NCT05046639 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which 10 mL 2% lidocaine is the first listed.

NCT05046639 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05046639 about?

NCT05046639 is a clinical study titled "Sciatic Block in Contralateral Limb Phantom and Residual Limb Pain". Participants with chronic, refractory phantom limb pain (PLP) or residual limb pain (RLP) for more than 6 months will be enrolled in this clinical trial. Aim: Define the attributable pain relief and functional improvement in participants with PLP/RLP after contralateral limb sciatic nerve block. Als...

What is the current status of trial NCT05046639?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2021-09-01. Estimated completion is 2023-07-26.

What interventions are being tested in trial NCT05046639?

The interventions under investigation include: 10 mL 2% lidocaine (DRUG), 10 mL preservative free saline (DRUG).

Who is sponsoring clinical trial NCT05046639?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.